JZ

Jill Zullo

Things Jill Says on Podcasts

Where to Find Them

Jill Zullo has been a guest on Grow Everything Biotech Podcast .

Recently: “207. Bio-Made in the USA: Jill Zullo Builds Domestic Scale at BioMADE” on Grow Everything Biotech Podcast (November 2026).

What They Said

“The novel product versus a drop-in, this is always a challenge, right? You think a drop-in will be faster, quicker, better. The challenge is that you have an incumbent that you have to beat the price or you have to beat the performance. … It is really difficult putting out a whole new functionality, because in order for them to adopt it, there's a significant cost on their side sometimes in how they use the material in their applications.” — Jill Zullo, Grow Everything Biotech Podcast

Asked whether BioMADE favors new biomaterials or cheap swaps for petrochemicals, Zullo draws on her industry experience to explain the trap on each side.

Grow Everything Biotech Podcast · 2026-11-13 Permalink → Listen →
Grow Everything Biotech Podcast Around 36:51 into the episode
Jill Zullo

Yeah, because it's different, right? It's different.

Erum Azeez Khan

…podcast that have partnered or members of BioMAID. So I would love to know a little bit about how BioMade evaluates strategic partnerships. What is your primary filter? Are you chasing novel high-performance biomaterials or cheap drop-in replacements for petrochemicals? What's the strategy here?

Jill Zullo

…scale and then from a scale out to sort of commercial. And so that technology roadmap has been developed and then we focus our investment specifically on those requirements. We also focus on, hey, if this product is of interest, maybe to the government itself. So we have both technology that will help accelerate a number of different products and products. So I think we kind of do it both ways. The novel product versus a drop-in, this is always a challenge, right? You think a drop-in will be faster, quicker, better. The challenge is that you have an incumbent that you have to beat the price or you have to beat the performance. And so that sometimes is really challenging, but sometimes just depending upon, I'm going to say that it is still needed because there might be a supply chain challenge there, right? So like going back to the earlier comments about how important assured protected supply chains are, there may be a drop-in that is needed. And so therefore, it makes great sense to develop that via a biological…

Erum Azeez Khan

Yeah, and then so you have the Department of Defense and being able to support the military effort of the warfighters and their needs and the Department of Defense can fund some of that. But from a commercial standpoint, you have industry. So you have the worlds of ZPG packaging. Can you just give…

Jill Zullo

And I'm going to kind of attack that maybe in a couple of different ways. One, for the government. So when we're working with the government, really trying to understand what are some of the supply chains again that are challenged. Where are some of the needed applications? Exciting area is the…

Erum Azeez Khan

Yeah, yeah. And also, I mean, just having that broader conversation with other members of government, other industry leaders that might not know much about biomanufacturing. Sometimes when I'm at like a party and meeting new people, I'm like, yeah, I talk a lot about biomanufacturing. They're like…

Speaker names come from our own diarization. The position is estimated from where the line sits in the episode.
“That it's all about the labor cost. You hear that? Oh, we can never compete. It's all about the labor cost. So yes, labor is more expensive here. It's growing in other places as well. The big challenge is also that capital is really intensive. U.S. steel right now, highest it's ever been, about 45% higher than the rest of the world. 80% of that is actually going into all the data centers that are being built, which is causing a shortage of U.S. steel. It's a full system. It's not really just labor.” — Jill Zullo, Grow Everything Biotech Podcast

In the rapid-fire round, Zullo was asked for the most overused myth about reshoring American manufacturing. Her answer ties reshoring costs to the AI data-center build-out. The steel figures are her own and were not sourced on the show.

Grow Everything Biotech Podcast · 2026-11-13 Permalink → Listen →
Grow Everything Biotech Podcast Around 47:01 into the episode
Jill Zullo

Oh, wow. Can you imagine?

Erum Azeez Khan

Yeah, exactly. That's what we need. Okay. Okay. Next one. What is the single most overused myth about reshoring American manufacturing?

Jill Zullo

That it's all about the labor cost. You hear that? Oh, we can never compete. It's all about the labor cost. So, yes, labor is more expensive here. It's growing in other places as well. The big challenge, it's not really always the labor. It's also capital is really intensive, right? U.S. steel right now, highest it's ever been, about 45% higher than the rest of the world. 80% of that is actually going into all the data centers that are being built, which is causing a shortage of U.S. steel. So it really, it's a full system. It's not really just labor.

Erum Azeez Khan

Wow. Oh, wow. So interesting. All right. Next one is: if BioMade had an official rally cry printed on its hard hat, what four words are on it?

Jill Zullo

Challenging one. But I'm going to say biology builds American strength.

Erum Azeez Khan

Oh, great. Oh.

Speaker names come from our own diarization. The position is estimated from where the line sits in the episode.
“Most people talk all about fermentation. And the real challenge, and I think the real art, is actually in the separation. … Let's say they need 96% of the desired product. The big thing isn't the 96%, it's the four. Or if you get a 99%, it's the 1%.” — Jill Zullo, Grow Everything Biotech Podcast

Asked why so many biotech startups run out of runway, Zullo points to downstream purification. The leftovers and trace impurities, not the headline yield, decide whether a process meets spec and pays.

Grow Everything Biotech Podcast · 2026-11-13 Permalink → Listen →
Grow Everything Biotech Podcast Around 29:13 into the episode
Jill Zullo

…but now you Can plan it, and so you'll know what to do at a larger scale when it's really a production run and you're trying to really convert that science into money. You really want to make sure that you know everything that can happen and how to respond to it. And that's what happens in a pilot.

Erum Azeez Khan

…are being used to talk about going from lab to pilot to more commercial scale. And we've heard about the fermentation, but can you tell us a bit more about the downstream processing aspect of this, a purification aspect? Why are so many biological startups, like why are they running out of runway?

Jill Zullo

Yeah, again, most people do. They talk all about fermentation. And the real challenge, and I think the real art is actually in the separation. And it's for a couple of different reasons. One, very often, especially if it's a novel, newer material, you actually don't even know what specification you need to hit. So, like, you don't know when you're there, when you're at that end game. Each molecule and each product can have sort of different ways to pull it out of the fermentation broth. So, what you're doing is in the fermenter, right, you're producing the product via a microorganism. The first thing that you usually do, if the product is produced and excreted out of a cell, which is the preferred route, then you pull all that cell mass out, which is so you can get most of like the thicker particulate material out. But now you have to use chemistries to figure out what is the most efficient way to pull your product of interest then out of, in essence, this broth or this soup. And just depending upon what it is, it could lead to…

Erum Azeez Khan

Yeah, and can you tell us a little bit more about how do you think about economics and downstream processing before you actually do it? Because it does require a lot of money to get to that scale. I would love to know how your projects with partners or even within Biomaid, how do you guys think…

Jill Zullo

Yeah, that's a very great point. And it is one of the main learnings that I think people are having, especially as smaller new companies starting up. We call it the T, so technical economic analysis. Sometimes gossip? It's no, or not a cup of tea. Yeah, it's where you really go in and you put out…

Erum Azeez Khan

Wow. Yeah, that's super useful. I could imagine for startups that might not be as well resourced, not even from a money side, but from an expertise side, to be able to think through something as complex as commercializing a biomanufacturing process. So that's incredible that you can think about and…

Speaker names come from our own diarization. The position is estimated from where the line sits in the episode.

Collections They Appear In